Awosika Olabola, Kim Lori, Mazhar Momina, Rengifo-Pardo Monica, Ehrlich Alison
Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA.
George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
Clin Cosmet Investig Dermatol. 2018 Jan 24;11:41-49. doi: 10.2147/CCID.S123329. eCollection 2018.
Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety in treating moderate-to-severe AD by reviewing data from Phase I-III clinical trials. Results suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating extended use of dupilumab and dupilumab in comparison to other agents are needed to establish long-term efficacy and safety.
特应性皮炎（AD）是一种常见的炎症性皮肤病，表现为湿疹样病变，常与过敏性鼻炎和哮喘相关。从历史上看，中重度疾病一直通过全身免疫抑制来治疗，如口服皮质类固醇，但会导致复发并产生限制副作用。由于最近在确定白细胞介素（IL）-4和IL-13为AD的关键介质方面取得了进展，已开发出新的生物制剂用于治疗。度普利尤单抗是一种最近获批的单克隆抗体，它靶向IL-4受体的α亚基，从而下调IL-4和IL-13的活性。本综述通过回顾I-III期临床试验的数据，讨论了度普利尤单抗的概况及其在治疗中重度AD方面的疗效和安全性潜力。结果表明，度普利尤单抗对AD显示出巨大的治疗前景。需要进一步研究度普利尤单抗的长期使用情况以及与其他药物相比的情况，以确定其长期疗效和安全性。
